MEDIA PACK 2010 - European Pharmaceutical Review
MEDIA PACK 2010 - European Pharmaceutical Review
MEDIA PACK 2010 - European Pharmaceutical Review
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
european<br />
pharmaceutical<br />
review<br />
european pharmaceutical review is the leading publication for<br />
information on technologies in drug discovery and manufacturing.<br />
Published bi-monthly, every issue offers a high level of technical and<br />
business contributions from the world’s leading pharmaceutical<br />
companies and academic institutions, coupled with a variety of<br />
exciting new features including interviews, updates and profiles.<br />
A Must Read<br />
european pharmaceutical review has been keeping the industry<br />
informed for more than 10 years and remains faithful to the key<br />
facets that serve its existing stakeholders so well; insights into<br />
current and emerging technologies, contributions from recognised<br />
figures in the life science community and quality presentation that<br />
makes every issue a reference tool for laboratories and offices<br />
across the world.<br />
“EPR is the means by which I remain informed of<br />
contemporary applications of cutting-edge technology. It<br />
provides a unique insight to appraise and evaluate<br />
innovations salient to pharmaceutical research, discovery<br />
and manufacturing. It’s an essential journal to remain<br />
advised and permit that vital insight to the future!”<br />
Ed Tidswell<br />
Snr. Director, Research,<br />
Technology Resources (Sterility Assurance), Baxter<br />
Healthcare Corp.<br />
“EPR is an excellent source for R&D relevant information<br />
written by renown experts of their field.”<br />
Dr. Christian Thirion<br />
CSO<br />
SIRION BIOTECH GmbH<br />
PAST CONTRIBUTORS INCLUDE:<br />
EDITORIAL BOARD • Professor Stephen Bustin<br />
To maintain our editorial integrity, and to ensure that each issue covers the topics that are of most<br />
concern to the industry, an independent editorial board provides guidance and expert analysis.<br />
Members include:<br />
Professor of Molecular Science, Kings College London<br />
• Dr Sheraz Gul<br />
Vice President & Head of Biology, <strong>European</strong> ScreeningPort<br />
2<br />
Dr Anne Katrin Werenskiold – Project Manager, Interaction Proteome<br />
Ken Leiper – Benson Associates<br />
Dr Gordon Alton – Dept. of Biochemistry, Pfizer Global R&D<br />
Matthew Moran – Director of the Irish <strong>Pharmaceutical</strong> and Chemical Manufacturers Association<br />
Dr Michael J Dunn – SFI Research Professor of Biomedical Proteomics, University College Dublin<br />
Don Clark – Pfizer Global R&D<br />
Dr Anthony Davies - HCA Research Facility Manager, Trinity College Dublin<br />
Dr Sheraz Gul - Vice President & Head of Biology, <strong>European</strong> ScreeningPort<br />
• Dr Jim Huggett<br />
Science Leader, LGC<br />
• Dr Stephen Minger<br />
Director of Stem Cell Biology, Kings College London<br />
• Dr Michael Miller<br />
President, Microbiology Consultants<br />
• Dr Anthony Davies<br />
HCA Research Facility Manager, Trinity College Dublin<br />
• Dr Holly Hilton<br />
Senior Principal Scientist, Bioinformatics, Roche
Change language